FDA warned trinexpharmacy.com for selling unapproved tramadol and misbranded Adderall without prescriptions to U.S. consumers.
What happened
FDA reviewed the website www.trinexpharmacy.com and found it offered unapproved and misbranded opioid and Schedule II stimulant drugs to U.S. consumers. The letter cites tramadol marketed as “Tramadol 100mg” made by Dimedics and amphetamine products marketed as “Adderall 10mg.” FDA says the site offered prescription drugs without requiring a prescription.
What FDA found
The website offered “Tramadol 100mg” made by Dimedics without an FDA-approved drug application.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website’s prescription drug labeling lacked adequate directions for use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.115(a)The website caused misbranded drugs to be introduced into interstate commerce by offering them for sale.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]The website offered prescription drugs, including “Adderall 10mg,” without a prescription.
FD&C Act section 503(b)(1) [21 U.S.C. § 353(b)(1)]Dispensing prescription drugs without a prescription made them misbranded while held for sale.
FD&C Act section 301(k) [21 U.S.C. § 331(k)]
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs to U.S. consumers and to notify FDA in writing within 15 working days of steps taken to address violations and prevent recurrence.
Who should pay attention
- online pharmacies selling to U.S. consumers
- companies offering prescription drugs online
- consumers buying opioids or stimulants online
This is a summary. Read the original letter on fda.gov.